以下文章来源于东四十条资本 ，作者鲁智高 东四十条资本 . 聚焦股权投资行业人物、事件、数据、研究、政策解读，提供专业视角和深度洞见 | 创投圈有趣的灵魂 服务千家医院，一年入账数亿元。 作者丨 鲁智高 编辑丨 王庆武 来源丨 东四十条资本 一家深圳明星公司成功登陆A股。 2月5日，北芯生命正式敲钟，成为重启科创板第五套标准后，该标准下第三家、医疗器械行业首家成功上市企业，也是2024年以来首家在科创板成功 上市的医疗器械企业。开盘不久，他们的股价较发行价17.52元上涨超218%，市值超过200亿元。 在海归博士宋亮的带领下，北芯生命成立以来便持续布局了冠状动脉疾病、外周血管疾病及房颤等领域，最终成功改写了中国冠状动脉疾病临床精准诊 断完全依赖进口产品的局面。 这番亮眼成绩的背后，离不开红杉中国、启明创投、国投创合、荷塘创投、松禾资本、倚锋投资、夏尔巴投资、博裕资本、德诚资本、太平医疗等机构 的支持。 伴随着IPO的钟声，众多投资人也终于迎来收获时刻。 海归博士创业，干出一个深圳明星IPO 北芯生命的故事，得从一位海归博士讲起。 将投中网设为"星标⭐"，第一时间收获最新推送 除了推出中国首个获批的自主创新6 ...

Core Viewpoint - The company reported its 1H25 performance, showing revenue and net profit growth, with a stable profitability outlook despite regional challenges [1][2]. Financial Performance - 1H25 revenue reached $83.55 million, a year-on-year increase of 5.9% - Net profit attributable to shareholders was $19.79 million, up 5.1% year-on-year - The performance aligns with the company's expectations [1]. Regional Growth Trends - Asia-Pacific (excluding China and Japan) revenue grew by 14%, driven by rapid growth in Indonesia and benefits from the Scoreflex TRIO balloon's market expansion - EMEA revenue increased by 17% - Japan's revenue declined by 15% due to a shift in sales strategy and reduced sales of low-priced coronary balloons, although sales expenses were significantly reduced - Revenue in China fell by 5%, with an increased proportion of revenue from centralized procurement products - U.S. revenue rose by 20%, despite tariff disruptions, with a positive outlook for coronary and peripheral balloon products in 2024 [1]. Profitability and Cost Management - 1H25 gross margin was 66.9%, down 3.8 percentage points year-on-year, attributed to declining sales in Japan and price reductions in China - Sales and management expense ratios decreased, while R&D expense ratios remained stable, leading to a stable net profit margin [1]. Global Business Network and Product Introduction - The company has established a mature and reliable direct sales team in over a dozen countries in Europe and Asia-Pacific - Recent acquisitions of distributors in Indonesia, South Korea, and Taiwan aim to enhance direct sales - The company has partnered with KaiLi Medical to distribute IVUS products in multiple regions, indicating a strong potential for introducing high-quality products [2]. Earnings Forecast and Valuation - The company maintains its earnings forecast for 2025/26, with a current price corresponding to a P/E ratio of 12/11 times - The target price has been raised by 36% to HKD 6.4, reflecting a 29% upside potential based on the overall recovery of the Hong Kong medical device sector and confidence in the company's global sales network [2].